
Opinion|Videos|January 31, 2025
CLL Treatment Landscape: Treatment-Naive Patients and BTK Inhibitors
Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14), and explore the continued role of ibrutinib in the CLL treatment landscape.
Advertisement
Episodes in this series

Provide an overview of the current landscape of first-line treatment options for CLL. What role do BTK inhibitors have in this landscape?
What continued role does ibrutinib have in the current CLL treatment landscape?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NYC Nurses Strike Enters Day 5 Amid Staffing, Safety, and Benefit Disputes
2
Detailed Liver Atlas Links Macrophage Activity to MASH Progression
3
CheckMate 9LA at 6 Years Shows Enduring Benefits From Dual Immunotherapy Plus Chemotherapy in Metastatic NSCLC
4
Value-Based Care Needs a Rebrand. Will 2026 Be the Year It Finally Gets One?
5
































































